BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Quinton Oswald Named Chief Executive Officer of SARcode


9/14/2010 8:23:20 AM

BRISBANE, Calif., Sept. 14 /PRNewswire/ -- SARcode Corporation, a privately-held biotechnology company focused on developing a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists, today announced that Quinton Oswald has joined the company as Chief Executive Officer.

Mr. Oswald brings significant commercial experience and management expertise to the CEO role. Most recently at Genentech, where he served as the Vice President & Business Unit Head for the Tissue Growth and Repair Business, Mr. Oswald was responsible for four key franchises Ophthalmology, Growth Hormone, Fibrinolytics and Cystic Fibrosis generating over $2.1 billion in annual sales. During his tenure at Genentech, Mr. Oswald oversaw the successful commercial launch of Lucentis® (ranibizumab) in 2006, the third fastest new product introduction in U.S. pharma history. Lucentis® was approved for the treatment of neovascular (wet) age-related macular degeneration (AMD) and reached sales of over $1 billion in 2009. This breakthrough therapy dramatically changed the treatment paradigm for retinal specialists by offering their patients the ability to stabilize and improve vision, instead of facing a progressive course toward blindness.

Prior to Genentech, Mr. Oswald led the North American Ophthalmology business for Novartis, which in conjunction with QLT, Inc. pioneered Visudyne® (verteporfin), the first drug treatment for wet AMD. Launched in 2000, Visudyne® replaced thermal laser therapy, offering a more targeted and less damaging treatment to slow vision decline.

"We are very pleased to have Quinton join our team at SARcode," said Robert Alexander, Director at Alta Partners and member of the SARcode Board of Directors. "He brings the right combination of sector knowledge and commercial expertise needed to lead SARcode through Phase III trials and on to the market. Quinton is a perfect fit for this role, given his long history in the ophthalmology space and his success in launching Lucentis®. While at Genentech, Quinton worked alongside Charles Semba, the Development Team Leader for Lucentis®, who today serves as SARcode's Chief Medical Officer. We expect this team will continue our rapid progress in the clinic, and guide our lead compound quickly through our final pivotal trials."

"I am very fortunate to have the opportunity to lead a company with the potential to deliver significant beneficial impact in a therapeutic area in which I not only have many years of operational experience, but also a passion to improve upon existing treatment," said Mr. Oswald, Chief Executive Officer of SARcode. "There are more than 20 million patients suffering from dry eye in the U.S. alone and up to 50 million patients worldwide. Yet most of them receive little relief from currently available drugs. Our lead product candidate, SAR 1118, has provided excellent Phase II results in both signs and symptoms. The study achieved these results within 12 weeks, demonstrating potential for more rapid relief than currently available therapies. I see big opportunities for this product and SARcode, and I am looking forward to being a part of this team."

Before joining Novartis, Mr. Oswald spent 16 years with Bristol Myers Squibb. After beginning his tenure with Bristol Myers in his home country of South Africa, he moved to Holland as General Manager to merge Bristol Myers and Squibb. Relocating to the U.S. in 1993, Mr. Quinton held line management roles as President for Asia, Middle East, and Africa, and President for Latin America and Canada.

About SARcode Corporation

SARcode is a venture-backed biopharmaceutical company focused on the development of best in class small molecule LFA-1 antagonists as novel nonsteroidal immunomodulators/anti-inflammatory agents for the treatment of T-cell mediated inflammatory diseases. Institutional investors include Alta Partners and Clarus Ventures.

For contact information, visit www.sarcode.com

SOURCE SARcode Corporation




SARcode
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES